| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Poster Presentation on VENTURE Study Results Evaluating Impact of VK2735 on Prediabetes and Cardiometabolic Status
Additional Poster Presentations Scheduled for American Heart Association Scientific Sessions 2025
SAN DIEGO, Oct. 29, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company's VK2735 obesity program will be the focus of two poster presentations at ObesityWeek® 2025, the annual meeting of The Obesity Society. VK2735 is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors being developed for the potential treatment of various metabolic disorders. Viking is evaluating both subcutaneous and oral formulations of VK2735 in clinical trials. ObesityWeek 2025 is being held November 4-7, 2025, in Atlanta, Georgia.
One ObesityWeek presentation will report results of an exploratory analysis from the company's Phase 2 VENTURE clinical trial, which evaluated 13 weeks of weekly treatment with a subcutaneous formulation of VK2735 in obese subjects. The exploratory analysis evaluated the impact of VK2735 treatment on the prevalence of prediabetes and metabolic syndrome over the 13-week study. A second presentation will highlight the design of the company's ongoing Phase 3 VANQUISH-1 study of subcutaneous VK2735 in patients with obesity or who are overweight with at least one weight-related co-morbid condition.
Viking will also make two presentations at the upcoming American Heart Association (AHA) Scientific Sessions 2025, which is being held November 7-10, 2025, in New Orleans, Louisiana. One presentation will share the design of the company's ongoing Phase 3 VANQUISH-2 study of subcutaneous VK2735 in Type 2 diabetes patients with obesity or who are overweight. The second poster will share results of an analysis of the prevalence of cardiometabolic conditions across different body mass index categories.
Posted In: VKTX
